QMIIZ Drug Patent Profile
✉ Email this page to a colleague
When do Qmiiz patents expire, and what generic alternatives are available?
Qmiiz is a drug marketed by Tersera and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in QMIIZ is meloxicam. There are twenty-two drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the meloxicam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Qmiiz
A generic version of QMIIZ was approved as meloxicam by AVONDALE PHARMS on June 1st, 2004.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for QMIIZ?
- What are the global sales for QMIIZ?
- What is Average Wholesale Price for QMIIZ?
Summary for QMIIZ
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for QMIIZ |
| DailyMed Link: | QMIIZ at DailyMed |
US Patents and Regulatory Information for QMIIZ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tersera | QMIIZ ODT | meloxicam | TABLET, ORALLY DISINTEGRATING;ORAL | 211210-001 | Oct 19, 2018 | DISCN | Yes | No | 8,545,879 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Tersera | QMIIZ ODT | meloxicam | TABLET, ORALLY DISINTEGRATING;ORAL | 211210-002 | Oct 19, 2018 | DISCN | Yes | No | 8,545,879 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
